Myocarditis

Myocarditis is an inflammatory disease of the myocardial wall, characterized by infiltration of inflammatory cells into the cardiac muscle, leading to myocyte necrosis, degeneration, and subsequent fibrosis. It can be acute, subacute, or chronic, and may result in focal or diffuse myocardial dysfunction, arrhythmias, and heart failure. In veterinary medicine, myocarditis is most commonly recognized in dogs and cats, often secondary to infectious agents, but it can also arise from toxic, metabolic, or immune-mediated causes. The clinical presentation ranges from subclinical infection to fulminant cardiogenic shock and sudden death. The diagnosis requires a high index of suspicion, supported by biomarkers, electrocardiography, echocardiography, and definitive confirmation via histopathology or molecular diagnostics.

The etiologies of myocarditis in dogs and cats are diverse. Infectious causes are the most frequently identified, with viral agents being prominent. In dogs, parvovirus (especially in puppies), canine distemper virus, adenovirus, and herpesvirus have been implicated. In cats, feline panleukopenia virus, feline leukemia virus (FeLV), and feline infectious peritonitis (FIP) coronavirus can cause myocarditis. Bacterial infections, such as those caused by Borrelia burgdorferi (Lyme disease), Bartonella spp., Streptococcus spp., Staphylococcus spp., and Escherichia coli, can lead to septic myocarditis, often secondary to bacteremia or endocarditis. Fungal agents, including Histoplasma capsulatum, Coccidioides immitis, and Aspergillus spp., are less common but can cause granulomatous myocarditis. Parasitic causes include Trypanosoma cruzi (Chagas disease) in endemic regions, Toxoplasma gondii, and larval migration of nematodes like Dirofilaria immitis (heartworm). Toxic causes include certain drugs (e.g., doxorubicin, 5-fluorouracil), heavy metals, and snake venoms. Metabolic disorders such as uremia and electrolyte imbalances can also induce myocardial inflammation. Immune-mediated myocarditis may occur as a primary autoimmune disorder or secondary to systemic immune diseases, such as systemic lupus erythematosus. Genetic predispositions are suspected in certain breeds, but specific mutations are not well-defined. Neoplastic infiltration (e.g., lymphoma, hemangiosarcoma) can mimic myocarditis but is not truly inflammatory.

Myocarditis is relatively uncommon in veterinary practice but can be underdiagnosed due to subclinical presentations. In dogs, viral myocarditis is most frequently seen in young, unvaccinated puppies, particularly with parvovirus, where myocardial involvement is a known complication. Canine distemper virus myocarditis is also more common in young dogs. In cats, infectious myocarditis is often associated with FeLV or FIP, with a higher incidence in multi-cat environments and shelters. Certain breeds may have a higher risk for immune-mediated myocarditis, such as Doberman Pinschers and Boxers, though these breeds are more commonly associated with dilated cardiomyopathy. Geographic distribution influences the prevalence of vector-borne diseases like Chagas disease (Trypanosoma cruzi) in South and Central America, and Lyme disease in endemic areas of North America and Europe. Seasonal patterns may be observed for tick-borne diseases. There is no clear sex predilection, but age is a significant factor, with younger animals more susceptible to infectious causes and older animals to neoplastic or degenerative conditions.

The pathophysiology of myocarditis involves a complex interplay between the inciting agent, the host immune response, and myocardial injury. Initially, the infectious agent or toxin directly damages myocytes, leading to necrosis and release of intracellular contents, including cardiac troponins. This triggers an innate immune response with activation of macrophages and natural killer cells, which release pro-inflammatory cytokines such as tumor necrosis factor-alpha, interleukins (IL-1, IL-6), and interferons. These cytokines further recruit neutrophils and lymphocytes to the myocardium. The adaptive immune response involves T-cell-mediated cytotoxicity against infected or damaged myocytes, and B-cell production of autoantibodies against cardiac antigens, which can perpetuate inflammation even after the inciting agent is cleared. The inflammatory infiltrate disrupts normal myocardial architecture, impairing contractility and electrical conduction. This can lead to systolic and diastolic dysfunction, reduced cardiac output, and arrhythmias. Chronic inflammation results in fibrosis and remodeling, which can progress to dilated cardiomyopathy-like phenotype. In severe cases, acute myocarditis can cause fulminant heart failure or fatal arrhythmias. Systemic effects include activation of the renin-angiotensin-aldosterone system and sympathetic nervous system, leading to fluid retention and vasoconstriction, further compromising cardiac function.

Predisposing factors for myocarditis include age (young animals are more susceptible to infectious causes), immune status (immunosuppression increases risk of opportunistic infections), vaccination status (lack of vaccination against parvovirus or distemper increases risk), and environmental exposure to vectors (ticks, mosquitoes) or endemic pathogens. Stress, overcrowding, and poor sanitation can facilitate transmission of infectious agents. Concurrent diseases, such as chronic kidney disease or diabetes mellitus, may increase susceptibility. Certain medications, particularly chemotherapeutic agents like doxorubicin, are known to cause myocardial injury. Genetic factors may play a role in immune-mediated myocarditis, with certain breeds having a higher incidence of autoimmune diseases. Nutritional deficiencies, such as taurine deficiency in cats, can predispose to myocardial dysfunction, though not directly to inflammation.

Clinical signs of myocarditis vary depending on the severity and duration of inflammation. In peracute cases, animals may present with sudden collapse, syncope, or sudden death due to fatal arrhythmias or cardiogenic shock. Acute myocarditis often presents with lethargy, weakness, anorexia, and signs of congestive heart failure, including tachypnea, dyspnea, cough (in dogs), and exercise intolerance. Physical examination may reveal fever, tachycardia or bradycardia, arrhythmias (premature beats, atrial fibrillation), weak femoral pulses, pale mucous membranes, prolonged capillary refill time, and possibly jugular venous distention. In subacute or chronic cases, signs may be more insidious, with progressive exercise intolerance, weight loss, and signs of right-sided heart failure such as ascites and peripheral edema (in dogs). Cats may present with respiratory distress due to pleural effusion. Auscultation may reveal a gallop rhythm or murmurs if concurrent valvular disease or dilation is present. Neurological signs may occur if embolic events or systemic inflammation affect the central nervous system.

Differential diagnoses for myocarditis include dilated cardiomyopathy (DCM), which presents with similar clinical signs but lacks inflammatory infiltrate on histopathology; endocarditis, which may cause valvular lesions and bacteremia; pericardial disease (e.g., pericardial effusion, constrictive pericarditis) causing signs of right-sided heart failure; congenital heart diseases (e.g., patent ductus arteriosus, ventricular septal defect) that may cause murmurs and heart failure; arrhythmogenic right ventricular cardiomyopathy (ARVC) in Boxers and cats; systemic hypertension leading to left ventricular hypertrophy and failure; hyperthyroidism in cats, which can cause tachycardia and myocardial hypertrophy; and neoplastic infiltration of the myocardium (e.g., hemangiosarcoma, lymphoma). Additionally, non-cardiac diseases such as pneumonia, sepsis, or systemic inflammatory response syndrome (SIRS) can cause tachycardia and elevated cardiac biomarkers, mimicking myocarditis. Definitive differentiation requires a combination of history, physical exam, biomarkers, imaging, and histopathology.

The diagnostic approach to suspected myocarditis begins with a thorough history and physical examination. If myocarditis is suspected, baseline diagnostics include a complete blood count (CBC), serum biochemistry profile, and urinalysis to assess for systemic inflammation, organ dysfunction, and infectious agents. Cardiac biomarkers, particularly serum cardiac troponin I (cTnI) and N-terminal pro-B-type natriuretic peptide (NT-proBNP), are highly sensitive and specific for myocardial injury and should be measured. Electrocardiography (ECG) is essential to detect arrhythmias and conduction disturbances. Thoracic radiographs are indicated to evaluate cardiac size, pulmonary vasculature, and evidence of congestive heart failure (pulmonary edema, pleural effusion). Echocardiography is the cornerstone of imaging, allowing assessment of myocardial function (ejection fraction, fractional shortening), chamber dimensions, wall thickness, and regional wall motion abnormalities. If infectious causes are suspected, specific serology or PCR testing for pathogens (e.g., parvovirus, distemper, Borrelia, Bartonella, Toxoplasma, Trypanosoma) should be performed. In cases where the diagnosis remains uncertain or for definitive confirmation, myocardial biopsy via endomyocardial biopsy (rarely performed in veterinary medicine) or post-mortem histopathology is the gold standard. Advanced imaging such as cardiac MRI may be used in referral centers to detect myocardial inflammation and fibrosis.

Laboratory findings in myocarditis are non-specific but supportive. CBC may reveal leukocytosis with a left shift in bacterial infections, lymphopenia in viral infections, or eosinophilia in parasitic or allergic causes. Anemia may be present in chronic disease. Serum biochemistry may show elevated liver enzymes (ALT, AST) due to hepatic congestion or hypoxia, elevated renal parameters (BUN, creatinine) if hypoperfusion or concurrent kidney disease, and electrolyte imbalances (e.g., hyperkalemia in severe acidosis). Cardiac troponin I (cTnI) is the most specific biomarker for myocardial injury; levels are typically elevated in myocarditis, often >0.1 ng/mL, and may be markedly elevated in acute cases. NT-proBNP is elevated in heart failure and can help differentiate cardiac from non-cardiac causes of respiratory distress. Inflammatory markers such as C-reactive protein (CRP) may be elevated. Blood gas analysis may reveal metabolic acidosis due to poor tissue perfusion. Urinalysis may show proteinuria or casts if concurrent renal involvement. Serology and PCR for specific infectious agents can confirm etiology. In cases of immune-mediated myocarditis, antinuclear antibody (ANA) testing may be positive.

Thoracic radiographs in myocarditis may show cardiomegaly, particularly left atrial and ventricular enlargement, pulmonary venous congestion, and interstitial or alveolar pulmonary edema in cases of left-sided heart failure. In right-sided heart failure, pleural effusion, ascites, and hepatomegaly may be evident. Echocardiography is the primary imaging modality. Findings include reduced left ventricular systolic function (decreased ejection fraction and fractional shortening), increased left ventricular internal dimensions in diastole and systole, and regional wall motion abnormalities. The myocardium may appear hyperechoic or heterogeneous in acute inflammation. In chronic cases, there may be thinning of the ventricular walls and fibrosis. Doppler echocardiography can assess diastolic function and detect valvular regurgitation. Cardiac MRI is the gold standard for non-invasive detection of myocardial inflammation and fibrosis in human medicine, but its use in veterinary medicine is limited to specialized centers. MRI findings include myocardial edema (increased T2 signal), hyperemia (early gadolinium enhancement), and fibrosis (late gadolinium enhancement). Computed tomography (CT) is less useful for myocardial assessment but may be used to rule out other thoracic pathology.

Cytological evaluation of pericardial fluid or myocardial aspirates is rarely performed due to the invasive nature and low yield. Histopathology from myocardial biopsy or necropsy is the definitive diagnostic method. Acute myocarditis is characterized by infiltration of inflammatory cells, primarily lymphocytes, macrophages, and neutrophils, with associated myocyte necrosis and degeneration. The inflammatory infiltrate may be focal, multifocal, or diffuse. Chronic myocarditis shows fibrosis, replacement of myocytes with fibrous tissue, and a mononuclear cell infiltrate. Special stains, such as Masson's trichrome for fibrosis and immunohistochemistry for specific pathogens (e.g., parvovirus, Toxoplasma), can aid in diagnosis. In bacterial myocarditis, microabscesses may be present. In parasitic myocarditis, organisms may be visible within the myocardium. Histopathological grading systems, such as the Dallas criteria used in human medicine, can be adapted to veterinary cases.

Treatment of myocarditis is multifaceted and depends on the underlying cause and severity of clinical signs. Emergency stabilization is crucial for animals with acute heart failure or life-threatening arrhythmias. This may include oxygen supplementation, diuretics (furosemide 1-4 mg/kg IV or IM q8-12h), vasodilators (e.g., sodium nitroprusside CRI at 0.5-10 mcg/kg/min), and positive inotropes (e.g., dobutamine CRI at 2-20 mcg/kg/min) for severe systolic dysfunction. Antiarrhythmic therapy is indicated for sustained or hemodynamically significant arrhythmias. For ventricular tachycardia, lidocaine (2-4 mg/kg IV bolus, then CRI at 25-80 mcg/kg/min) or amiodarone (10-15 mg/kg PO q12h) may be used. For atrial fibrillation, diltiazem (0.5-1.5 mg/kg PO q8h) or digoxin (0.005-0.01 mg/kg PO q12h) can be considered. Specific therapy for infectious causes is essential. For bacterial myocarditis, broad-spectrum antibiotics (e.g., amoxicillin-clavulanate 12.5-25 mg/kg PO q8-12h, or enrofloxacin 5-10 mg/kg PO q24h) should be initiated based on culture and sensitivity. For viral myocarditis, supportive care is the mainstay, but antiviral drugs (e.g., oseltamivir for parvovirus) may be considered. For parasitic causes, antiparasitic drugs (e.g., doxycycline for Bartonella, or benznidazole for Chagas) are used. Immunosuppressive therapy (e.g., prednisone 1-2 mg/kg PO q24h, or cyclosporine) is controversial but may be considered in immune-mediated myocarditis when infectious causes have been ruled out. Supportive care includes rest, nutritional support, and management of congestive heart failure with ACE inhibitors (e.g., enalapril 0.5 mg/kg PO q12h) and beta-blockers (e.g., carvedilol 0.1-0.5 mg/kg PO q12h) once stable.

The prognosis for myocarditis varies widely depending on the etiology, severity, and response to therapy. Acute viral myocarditis in puppies has a guarded to poor prognosis, with high mortality if severe. Bacterial myocarditis carries a better prognosis if treated early with appropriate antibiotics. Parasitic myocarditis, such as Chagas disease, has a chronic progressive course with a poor long-term prognosis. Immune-mediated myocarditis may respond to immunosuppressive therapy, but the prognosis is variable. Negative prognostic indicators include severe systolic dysfunction (ejection fraction <30%), refractory arrhythmias, elevated troponin levels that do not normalize, and the development of chronic heart failure. With aggressive treatment, some animals may recover fully, but others may progress to chronic myocardial failure requiring long-term cardiac medications. The overall mortality rate for clinical myocarditis is estimated at 20-50% in dogs, but subclinical cases may have a better outcome.

Follow-up care for myocarditis involves regular re-evaluations to monitor cardiac function and adjust therapy. Initially, re-check examinations should be performed every 1-2 weeks until clinical signs stabilize. Serial measurements of cardiac troponin I and NT-proBNP are useful to assess myocardial injury and response to treatment. Echocardiography should be repeated at 1, 3, and 6 months after diagnosis to evaluate changes in cardiac size and function. Electrocardiography should be performed at each re-check to monitor for arrhythmias. If the underlying cause is infectious, repeat serology or PCR may be indicated to confirm clearance of the organism. Long-term management may include continued administration of cardiac medications (ACE inhibitors, beta-blockers, diuretics) and periodic monitoring every 3-6 months. Owners should be educated on recognizing signs of heart failure and arrhythmias. In cases of immune-mediated myocarditis, immunosuppressive therapy may be tapered slowly over several months while monitoring for relapse.

Pearls: 1) Always consider myocarditis in young animals with acute onset of heart failure or arrhythmias, especially if they are unvaccinated. 2) Cardiac troponin I is a highly sensitive and specific biomarker for myocardial injury; a normal value makes myocarditis unlikely. 3) Echocardiography may show regional wall motion abnormalities that are not typical of dilated cardiomyopathy. 4) Early aggressive antiarrhythmic therapy can be life-saving. 5) In endemic areas, consider vector-borne diseases as a cause of myocarditis. Pitfalls: 1) Do not administer immunosuppressive doses of corticosteroids without ruling out infectious causes, as this can worsen the disease. 2) Avoid using dobutamine in animals with arrhythmias, as it can exacerbate them. 3) Do not rely solely on radiographs to diagnose heart failure; echocardiography is essential. 4) Failure to perform a thorough diagnostic workup may lead to misdiagnosis of dilated cardiomyopathy and inappropriate treatment. 5) Do not discontinue antiarrhythmic therapy abruptly; taper gradually to avoid rebound arrhythmias.

Drug protocols for myocarditis are based on the underlying cause and clinical signs. For congestive heart failure: Furosemide (1-4 mg/kg IV, IM, SC, or PO q8-12h; adjust dose based on response). Enalapril (0.5 mg/kg PO q12h) or benazepril (0.25-0.5 mg/kg PO q24h). Pimobendan (0.25-0.3 mg/kg PO q12h) for systolic dysfunction. For arrhythmias: Lidocaine (2-4 mg/kg IV bolus over 1-2 minutes, then CRI at 25-80 mcg/kg/min) for ventricular tachycardia. Procainamide (10-20 mg/kg PO q6-8h) as an alternative. Amiodarone (10-15 mg/kg PO q12h for 7 days, then 5-10 mg/kg PO q24h) for refractory cases. Diltiazem (0.5-1.5 mg/kg PO q8h) for atrial fibrillation or supraventricular tachycardia. Digoxin (0.005-0.01 mg/kg PO q12h) for atrial fibrillation with concurrent heart failure. For bacterial myocarditis: Amoxicillin-clavulanate (12.5-25 mg/kg PO q8-12h) or enrofloxacin (5-10 mg/kg PO q24h) for 4-6 weeks. For rickettsial diseases: Doxycycline (5-10 mg/kg PO q12h) for 14-28 days. For parasitic causes: Fenbendazole (50 mg/kg PO q24h for 3-5 days) for nematodes; for Chagas, benznidazole (5-7 mg/kg PO q12h for 60 days) or nifurtimox (2-5 mg/kg PO q8h for 90 days). For immune-mediated myocarditis: Prednisone (1-2 mg/kg PO q24h) with tapering over 3-6 months; cyclosporine (5-10 mg/kg PO q24h) as an adjunct. Always adjust dosages for renal or hepatic impairment and monitor for drug interactions.

Evidence-based literature on myocarditis in veterinary medicine is limited, but several key studies and consensus statements provide guidance. The ACVIM consensus statement on the diagnosis and treatment of canine dilated cardiomyopathy (DCM) includes myocarditis as a differential diagnosis. Studies have shown that cardiac troponin I is a sensitive marker for myocardial injury in dogs with parvovirus infection, and elevated levels correlate with severity. Research on Chagas disease in dogs has demonstrated the efficacy of benznidazole in reducing parasitemia and improving survival. A retrospective study on feline myocarditis associated with FIP found that affected cats had a poor prognosis. The use of immunosuppressive therapy in myocarditis is controversial; a study in dogs with suspected immune-mediated myocarditis showed some benefit with prednisone, but larger trials are lacking. The European Society of Cardiology (ESC) guidelines for the management of myocarditis in humans are often extrapolated to veterinary patients, but species-specific differences must be considered. Overall, there is a need for more prospective, controlled studies to establish evidence-based treatment protocols for myocarditis in dogs and cats.